Antimicrobial resistance prediction in Neisseria gonorrhoeae: Current status and future prospects
2022 (English)In: Expert Review of Molecular Diagnostics, ISSN 1473-7159, E-ISSN 1744-8352, Vol. 22, no 1, p. 29-48Article, review/survey (Refereed) Published
Abstract [en]
Introduction: Several nucleic acid amplification tests (NAATs), mostly real-time PCRs, to detect antimicrobial resistance (AMR) determinants and predict AMR in Neisseria gonorrhoeae are promising, and some may be ready to apply at the point-of-care (POC), but important limitations remain with most NAATs. Next-generation sequencing (NGS) can overcome many of these limitations.
Areas covered: Recent advances, with main focus on publications since 2017, in the development and use of NAATs and NGS to predict gonococcal AMR for surveillance and clinical use, and pros and cons of these tests as well as future perspectives for appropriate use of molecular AMR prediction for N. gonorrhoeae.
Expert Commentary: NAATs and/or NGS for AMR prediction should supplement culture-based AMR surveillance, which will remain because it detects also AMR due to unknown AMR determinants, and translation into POC tests is imperative for the end-goal of individualized treatment, sparing ceftriaxone±azithromycin. Several challenges for direct testing of clinical, especially pharyngeal, specimens and for accurate prediction of cephalosporins and azithromycin resistance, especially using NAATs, remain. The choice of AMR prediction assay needs to carefully consider the intended use of the assay; limitations intrinsic to the AMR prediction technology, algorithms and specific to chosen methodology; specimen types analyzed; and cost-effectiveness.
Place, publisher, year, edition, pages
Expert Reviews Ltd. , 2022. Vol. 22, no 1, p. 29-48
Keywords [en]
23S rRNA, Next-generation sequencing, Whole-genome sequencing, azithromycin, ceftriaxone, ciprofloxacin, gyrA, molecular diagnosis, nucleic acid amplification test (NAAT), penA
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-95784DOI: 10.1080/14737159.2022.2015329ISI: 000737800100001PubMedID: 34872437Scopus ID: 2-s2.0-85121852943OAI: oai:DiVA.org:oru-95784DiVA, id: diva2:1617857
Note
Funding agencies:
Örebro County Council Research Committee
Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden
2021-12-082021-12-082022-09-30Bibliographically approved